Accuracy of Real-Time Continuous Glucose Monitoring System in Hospitalized Patients with Diabetes and Chronic Kidney Disease.

IF 7.4 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Diabetes technology & therapeutics Pub Date : 2026-09-01 Epub Date: 2026-02-16 DOI:10.1177/15209156261423902
Yoshinori Kakutani, Tomoaki Morioka, Shoko Miyamoto, Yuka Natsuki, Yuya Miki, Akinobu Ochi, Masanori Emoto
{"title":"Accuracy of Real-Time Continuous Glucose Monitoring System in Hospitalized Patients with Diabetes and Chronic Kidney Disease.","authors":"Yoshinori Kakutani, Tomoaki Morioka, Shoko Miyamoto, Yuka Natsuki, Yuya Miki, Akinobu Ochi, Masanori Emoto","doi":"10.1177/15209156261423902","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Real-time continuous glucose monitoring (CGM) systems are beneficial for patients with diabetes by providing a comprehensive assessment of glycemic status and reducing hypoglycemia. However, their performance in patients with both diabetes and chronic kidney disease (CKD) during hospitalization remains unclear. This study aimed to evaluate the accuracy of real-time CGM in hospitalized patients with diabetes and CKD.</p><p><strong>Research design and methods: </strong>We conducted a prospective observational study including 52 patients with diabetes after excluding those with acute kidney injury, active glomerulonephritis, requiring intensive care, or undergoing hemodialysis. Participants were categorized by estimated glomerular filtration rate (eGFR, mL/min/1.73 m<sup>2</sup>) into G1-2 (≥60), G3 (30-59), and G4-5 (<30). Capillary glucose values were measured with a validated point-of-care (POC) device and paired with corresponding real-time CGM (G6, Dexcom) readings. Accuracy was assessed by mean absolute relative difference (MARD), correlation analyses, Bland-Altman plots, and consensus error grid (CEG) analyses.</p><p><strong>Results: </strong>A total of 1603 paired glucose values were analyzed, including 752 in G1/2, 571 in G3, and 280 in G4/5. CGM and POC glucose were strongly correlated (<i>r</i> = 0.91, <i>P</i> < 0.001). The overall MARD was 17.0%, with group-specific values of 19.4% in G1/2, 15.5% in G3, and 13.5% in G4/5 (<i>P</i> < 0.001). Bland-Altman plots showed smaller bias and narrower limits of agreement in advanced CKD. CEG analyses demonstrated high agreement, with >99% of values within clinically acceptable zones.</p><p><strong>Conclusions: </strong>The Dexcom G6 demonstrated reliable accuracy in hospitalized patients with diabetes and CKD, with better performance in advanced CKD. These findings support its clinical utility in this population.</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":"958-968"},"PeriodicalIF":7.4000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15209156261423902","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/16 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Real-time continuous glucose monitoring (CGM) systems are beneficial for patients with diabetes by providing a comprehensive assessment of glycemic status and reducing hypoglycemia. However, their performance in patients with both diabetes and chronic kidney disease (CKD) during hospitalization remains unclear. This study aimed to evaluate the accuracy of real-time CGM in hospitalized patients with diabetes and CKD.

Research design and methods: We conducted a prospective observational study including 52 patients with diabetes after excluding those with acute kidney injury, active glomerulonephritis, requiring intensive care, or undergoing hemodialysis. Participants were categorized by estimated glomerular filtration rate (eGFR, mL/min/1.73 m2) into G1-2 (≥60), G3 (30-59), and G4-5 (<30). Capillary glucose values were measured with a validated point-of-care (POC) device and paired with corresponding real-time CGM (G6, Dexcom) readings. Accuracy was assessed by mean absolute relative difference (MARD), correlation analyses, Bland-Altman plots, and consensus error grid (CEG) analyses.

Results: A total of 1603 paired glucose values were analyzed, including 752 in G1/2, 571 in G3, and 280 in G4/5. CGM and POC glucose were strongly correlated (r = 0.91, P < 0.001). The overall MARD was 17.0%, with group-specific values of 19.4% in G1/2, 15.5% in G3, and 13.5% in G4/5 (P < 0.001). Bland-Altman plots showed smaller bias and narrower limits of agreement in advanced CKD. CEG analyses demonstrated high agreement, with >99% of values within clinically acceptable zones.

Conclusions: The Dexcom G6 demonstrated reliable accuracy in hospitalized patients with diabetes and CKD, with better performance in advanced CKD. These findings support its clinical utility in this population.

糖尿病和慢性肾病住院患者实时连续血糖监测系统的准确性
目的:实时连续血糖监测(CGM)系统通过提供全面的血糖状态评估和降低低血糖,对糖尿病患者有益。然而,它们在糖尿病和慢性肾脏疾病(CKD)患者住院期间的表现尚不清楚。本研究旨在评估糖尿病合并CKD住院患者实时CGM的准确性。研究设计和方法:我们进行了一项前瞻性观察性研究,包括52例糖尿病患者,排除了急性肾损伤、活动性肾小球肾炎、需要重症监护或进行血液透析的患者。根据估计的肾小球滤过率(eGFR, mL/min/1.73 m2)将参与者分为G1-2(≥60),G3(30-59)和G4-5(结果:共分析了1603对葡萄糖值,其中G1/2 752人,G3 571人,G4/5 280人。CGM与POC血糖呈正相关(r = 0.91, P < 0.001)。总体MARD为17.0%,G1/2组为19.4%,G3组为15.5%,G4/5组为13.5% (P < 0.001)。Bland-Altman图显示晚期CKD的偏倚较小,一致性范围较窄。CEG分析显示高度一致,bbbb99 %的值在临床可接受范围内。结论:Dexcom G6在糖尿病合并CKD住院患者中具有可靠的准确性,在晚期CKD中表现更好。这些发现支持其在该人群中的临床应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书